189 related articles for article (PubMed ID: 34043041)
1. The socioeconomic burden of facioscapulohumeral muscular dystrophy.
Blokhuis AM; Deenen JCW; Voermans NC; van Engelen BGM; Kievit W; Groothuis JT
J Neurol; 2021 Dec; 268(12):4778-4788. PubMed ID: 34043041
[TBL] [Abstract][Full Text] [Related]
2. The facioscapulohumeral muscular dystrophy - health index: Italian validation of a disease-specific measure of symptomatic burden.
Carraro E; Greco LC; Lizio A; Beretta M; Pozzi S; Casiraghi J; Becchiati S; Beshiri F; Frisoni MC; Iossa F; Heatwole C; Sansone V
Disabil Rehabil; 2024 May; 46(10):2130-2137. PubMed ID: 37194629
[TBL] [Abstract][Full Text] [Related]
3. Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe.
Cavazza M; Kodra Y; Armeni P; De Santis M; López-Bastida J; Linertová R; Oliva-Moreno J; Serrano-Aguilar P; Posada-de-la-Paz M; Taruscio D; Schieppati A; Iskrov G; Péntek M; von der Schulenburg JM; Kanavos P; Chevreul K; Persson U; Fattore G;
Eur J Health Econ; 2016 Apr; 17 Suppl 1():19-29. PubMed ID: 27038625
[TBL] [Abstract][Full Text] [Related]
4. Socioeconomic burden of amyotrophic lateral sclerosis, myasthenia gravis and facioscapulohumeral muscular dystrophy.
Schepelmann K; Winter Y; Spottke AE; Claus D; Grothe C; Schröder R; Heuss D; Vielhaber S; Mylius V; Kiefer R; Schrank B; Oertel WH; Dodel R
J Neurol; 2010 Jan; 257(1):15-23. PubMed ID: 19629566
[TBL] [Abstract][Full Text] [Related]
5. The Facioscapulohumeral Muscular Dystrophy-Health Index: Development and evaluation of a disease-specific outcome measure.
Varma A; Weinstein J; Seabury J; Rosero S; Engebrecht C; Wagner E; Zizzi C; Luebbe EA; Dilek N; McDermott MP; Kissel J; Sansone V; Heatwole C
Muscle Nerve; 2023 Oct; 68(4):422-431. PubMed ID: 37610084
[TBL] [Abstract][Full Text] [Related]
6. Gastrointestinal and genitourinary symptoms in facioscapulohumeral muscular dystrophy: Prevalence and impact.
Cole MR; Cooper CS; Hanna EM; Zimmerman MB; Kinoshita J; Mathews KD
Muscle Nerve; 2024 Mar; 69(3):325-333. PubMed ID: 38158588
[TBL] [Abstract][Full Text] [Related]
7. Facioscapulohumeral Muscular Dystrophy European Patient Survey: Assessing Patient Reported Disease Burden and Preferences in Clinical Trial Participation.
McNiff MM; Hawkins S; Haase B; Bullivant J; McIver T; Mitelman O; Emery N; Tasca G; Voermans N; Diaz-Manera J
J Neuromuscul Dis; 2024; 11(2):459-472. PubMed ID: 38277300
[TBL] [Abstract][Full Text] [Related]
8. Understanding the socioeconomic costs of dystrophic epidermolysis bullosa in Europe: a costing and health-related quality of life study.
Angelis A; Mellerio JE; Kanavos P
Orphanet J Rare Dis; 2022 Sep; 17(1):346. PubMed ID: 36068590
[TBL] [Abstract][Full Text] [Related]
9. Social and economic costs and health-related quality of life in non-institutionalised patients with cystic fibrosis in the United Kingdom.
Angelis A; Kanavos P; López-Bastida J; Linertová R; Nicod E; Serrano-Aguilar P;
BMC Health Serv Res; 2015 Sep; 15():428. PubMed ID: 26416027
[TBL] [Abstract][Full Text] [Related]
10. Medication adherence in patients with myotonic dystrophy and facioscapulohumeral muscular dystrophy.
Fitzgerald BP; Conn KM; Smith J; Walker A; Parkhill AL; Hilbert JE; Luebbe EA; Moxley RT
J Neurol; 2016 Dec; 263(12):2528-2537. PubMed ID: 27734165
[TBL] [Abstract][Full Text] [Related]
11. Exploring the influence of smoking and alcohol consumption on clinical severity in patients with facioscapulohumeral muscular dystrophy.
Vincenten SCC; Mul K; Schreuder THA; Voermans NC; Horlings CGC; van Engelen BGM
Neuromuscul Disord; 2021 Sep; 31(9):824-828. PubMed ID: 34407911
[TBL] [Abstract][Full Text] [Related]
12. Socioeconomic costs and health-related quality of life in juvenile idiopathic arthritis: a cost-of-illness study in the United Kingdom.
Angelis A; Kanavos P; López-Bastida J; Linertová R; Serrano-Aguilar P;
BMC Musculoskelet Disord; 2016 Aug; 17():321. PubMed ID: 27484740
[TBL] [Abstract][Full Text] [Related]
13. Social/economic costs and quality of life in patients with haemophilia in Europe.
Cavazza M; Kodra Y; Armeni P; De Santis M; López-Bastida J; Linertová R; Oliva-Moreno J; Serrano-Aguilar P; Posada-de-la-Paz M; Taruscio D; Schieppati A; Iskrov G; Gulácsi L; von der Schulenburg JM; Kanavos P; Chevreul K; Persson U; Fattore G;
Eur J Health Econ; 2016 Apr; 17 Suppl 1():53-65. PubMed ID: 27048374
[TBL] [Abstract][Full Text] [Related]
14. The French National Registry of patients with Facioscapulohumeral muscular dystrophy.
Guien C; Blandin G; Lahaut P; Sanson B; Nehal K; Rabarimeriarijaona S; Bernard R; Lévy N; Sacconi S; Béroud C
Orphanet J Rare Dis; 2018 Dec; 13(1):218. PubMed ID: 30514324
[TBL] [Abstract][Full Text] [Related]
15. Living with facioscapulohumeral muscular dystrophy during the first two COVID-19 outbreaks: a repeated patient survey in the Netherlands.
Deenen JCW; Kools J; Greco A; Thewissen R; van de Put W; Lanser A; Joosten LAB; Verbeek ALM; van Engelen BGM; Voermans NC
Acta Neurol Belg; 2024 Apr; 124(2):559-566. PubMed ID: 38218752
[TBL] [Abstract][Full Text] [Related]
16. Estimating Societal Cost of Illness and Patients' Quality of Life of Duchenne Muscular Dystrophy in Egypt.
Shehata ZH; Rabea H; El Sherif R; Abdelrahim ME; Dawoud DM
Value Health Reg Issues; 2023 Jan; 33():10-16. PubMed ID: 36162195
[TBL] [Abstract][Full Text] [Related]
17. If you build a rare disease registry, will they enroll and will they use it? Methods and data from the National Registry of Myotonic Dystrophy (DM) and Facioscapulohumeral Muscular Dystrophy (FSHD).
Hilbert JE; Kissel JT; Luebbe EA; Martens WB; McDermott MP; Sanders DB; Tawil R; Thornton CA; Moxley RT;
Contemp Clin Trials; 2012 Mar; 33(2):302-11. PubMed ID: 22155025
[TBL] [Abstract][Full Text] [Related]
18. Burden of a multiple sclerosis relapse: the patient's perspective.
Oleen-Burkey M; Castelli-Haley J; Lage MJ; Johnson KP
Patient; 2012; 5(1):57-69. PubMed ID: 22217263
[TBL] [Abstract][Full Text] [Related]
19. The Dutch registry for facioscapulohumeral muscular dystrophy: Cohort profile and longitudinal patient reported outcomes.
Kools J; Deenen JC; Blokhuis AM; Verbeek AL; Voermans NC; van Engelen BG
Neuromuscul Disord; 2023 Dec; 33(12):964-971. PubMed ID: 38016873
[TBL] [Abstract][Full Text] [Related]
20. Patient-identified disease burden in facioscapulohumeral muscular dystrophy.
Johnson NE; Quinn C; Eastwood E; Tawil R; Heatwole CR
Muscle Nerve; 2012 Dec; 46(6):951-3. PubMed ID: 23225386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
